LASP1 and chronic myelogenous leukemia, BCR-ABL1 positive: Thereby, our results provide the first cell‐based confirmation of the bioinformatics data by Yeung and colleagues, who predicted that a reduced LASP1 concentration might be unfavourable during CML progression, as they observed lower LASP1 mRNA levels in blast crisis patients.13